HealthDay News — For women, sex hormone-binding globulin (SHBG) and total estradiol are associated with the risk of type 2 diabetes, according to research published in Diabetes.
Taulant Muka, MD, from the Erasmus Medical Center in Rotterdam, Netherlands, and colleagues analyzed data from 3117 postmenopausal women participants of the Rotterdam Study to examine whether endogenous sex hormones and SHBG correlate with the risk of incident type 2 diabetes. They also conducted a meta-analysis of studies examining the prospective correlation of endogenous sex hormones and SHBG with type 2 diabetes.
The researchers identified 384 incident cases of type 2 diabetes in the RS during a median follow-up of 11.1 years. There was no correlation for total or bioavailable testosterone with type 2 diabetes. An inverse correlation was seen for SHBG with the risk of type 2 diabetes, while total estradiol correlated with elevated type 2 diabetes risk.
In a meta-analysis of 13 studies involving more than 1912 incident type 2 diabetes cases, increased risk of type 2 diabetes was seen with low levels of SHBG and high levels of total estradiol. The correlation of endogenous sex hormones and type 2 diabetes was only seen in postmenopausal women; menopausal status did not impact the correlation of SHBG with type 2 diabetes.
“SHBG and total estradiol are independent risk factors for the development of type 2 diabetes in women,” the researchers wrote.
Disclosures: Several authors disclosed financial ties to nutrition and biopharmaceutical companies, including Metagenics, which funded the study.
- Muka T, Nano J, Jaspers L, et al. Associations of steroid sex hormones and sex hormone-binding globulin with the risk of type 2 diabetes in women: a population-based cohort study and meta-analysis. Diabetes. 2016 Oct 10. doi:10.2337/db16-0473 [Epub ahead of print].